medigraphic.com
SPANISH

Revista Médica de Costa Rica y Centroamérica

Colegio de Medicos y Cirujanos República de Costa Rica
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2012, Number 603

<< Back Next >>

Rev Med Cos Cen 2012; 69 (603)

Tumor de gist: presentacion de dos casos clinicos

Pedroso RM, Mora PT, Hernández MF, Castillo AR
Full text How to cite this article

Language: Spanish
References: 10
Page: 373-377
PDF size: 199.30 Kb.


Key words:

Gastrointestinal stromal tumors, Gist, leiomyomas, leiomyosarcomas, c-kit, CD117.

ABSTRACT

Gastrointestinal stromal tumors (GIST) constitute the majority of mesenchymal tumors involving the gastrointestinal tract. It is estimated that there are 2500 to 6000 cases per year in the U.S. Although the clinical presentation varies depending on the tumor size and anatomical location, most tumor are found incidentally at the time of endoscopic or radiologic imaging. Gists arise most frequently in the stomach (60-70%), followed by the small intestine (20-25%), colon and rectum (5%), and esophagus (‹5%). Most Gist are sporadic and, in 95% of cases solitary. Most patients with GISTs present in the fifth to the seventh decades of life, and these tumors are equally distributed between the genders. Symptoms of these lesions include pain and gastrointestinal bleeding, with abdominal mass a frequent finding. Surgical resection remains the treatment of choice for GISTs. However, despite complete surgical resection, the majority of patients (76%) will suffer local recurrence. This article documents two cases of patients with GIST with different clinical features. This is a 26 year old female patient with an abdominal mass as a sign of submission and the other 67 years male patient who presents with gastrointestinal bleeding as the initial manifestation.


REFERENCES

  1. Feig B, Berger D, Fuhrman G. The M.D. Andersor Surgical Oncology Handbook, 4th Edicion, Philadelphia Pennsylvania: Lippincott Williams and Wilkins, 2006: 136-138, 235-236.

  2. Saund M, Demetri G, Ashley S. Gastrointestinal stromal tumors. Curr Opin Gastroenterol. 2004; Vol 20: 89-94

  3. Mulholland M, et al. Greenfield’s Surgery Scientific Principles and Practice, 5th Edicion, Philadelphia Pennsylvania: Lippincott Williams and Wilkins, 2011: 273, 794-796, 2032.

  4. Townsend C, Beauchamp D, Evers B, Mattox K. Sabiston Textbook of Surgery, 17 th edicion, Philadelphia Pennsylvania: Elsevier, 2004: 811, 1116-1117.

  5. Gregory B. Davis, M.D., Blanchard, Kay, M.D., Hatch, George, M.D., Wertheimer-Hatch, Laura, M.D., Hatch, Kathryn, B.S., Foster, Roger Jr., M.D., Skandalakis, John E., M.D. Tumors of the stomach. World J Surg. 2000; 24: 412-420.

  6. Arroyo L, ALvarez H, Acuña J. Tumor gastrico estromal como causa de sangrado digestivo. Acta med costarric. 2006; Vol 48: 131-134

  7. Eizaguirre B, Burgos J. Tumores GIST. Revision de la literatura. Rev Esp Patol. 2006; Vol 39: 209-218.

  8. Oyanedel R, O’Brien A, Pizarro A, Zamora E, Menias C. TUMOR ESTROMAL GASTROINTESTINAL (GIST): FORMAS DE PRESENTACION. Rev. chil. Radiol. 2005; Vol 11: 13-18.

  9. Tzen C-Y, Mau B-L. Analysis of CD117 negative gastrointestinal stromal tumors. World J Gastroenterol 2005; Vol 11: 1052-1055.

  10. Demetri G, von Mehren M, Blanke C, et al. Efficacy and safety of Imatinib mesylate in advanced gastriontestinal stromal tumors. N. Engl




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med Cos Cen. 2012;69